This article is an erratum on:
Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
Frontiers Production Officeby Boudou C, Mattio L, Koval A, Soulard V and Katanaev VL (2022). Front. Pharmacol. 13:1045102. doi: 10.3389/fphar.2022.1045102
An omission to the Funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Geneva.”
The original version of this article has been updated.
Keywords: Wnt signaling, triple-negative breast cancer, β-catenin, cancer survival, medicinal chemistry, structure activity relationship, thienopyrimidine, quinazoline
Citation: Frontiers Production Office (2023) Erratum: Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors. Front. Pharmacol. 14:1173490. doi: 10.3389/fphar.2023.1173490
Received: 24 February 2023; Accepted: 24 February 2023;
Published: 07 March 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn